Marshall Health — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$14,363	3
2022	Research	$180	1
2021	Research	$33,446	7
2020	Research	$90,027	14
2019	Research	$32,639	16

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $130,472 22 payments
Alexion Pharmaceuticals, Inc. $17,150 1 payment
Upsher-Smith Laboratories LLC $14,363 3 payments
Portola Pharmaceuticals, Inc. $8,490 14 payments
AbbVie, Inc. $180 1 payment

Studies the money was for Research payments · program years 2019–2025

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $88,110 13 payments
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $22,677 1 payment
A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor $17,150 1 payment
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $15,216 5 payments
P255-501 $14,363 3 payments
Recombinant Factor Xa Inhibitor Antidote $8,490 14 payments
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $1,918 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $1,473 1 payment
Chronic Idiopathic Constipation (Cic),Irritable Bowel Syndrome With Constipation (Ibs-C) $1,080 1 payment
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) $180 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.